MOUNTAIN
VIEW, Calif., May 12, 2023
/CNW/ - Willow Biosciences Inc. ("Willow" or the
"Company") (TSX: WLLW) (OTCQB: CANSF) is pleased to
announce the voting results from its annual general and special
meeting of shareholders held on May 12,
2023 (the "Meeting"). A total of 57,318,575 common
shares, representing approximately 46.329% of the Company's issued
and outstanding shares were represented at the meeting.
The shareholders approved the setting of the number of directors
of Willow at 9 directors, and the following nominees were elected
as directors of Willow for the ensuing year with the specific
voting results being as follows:
|
Votes For
|
Votes
Withheld
|
Director
|
#
|
%
|
#
|
%
|
Dr. Peter
Seufer-Wasserthal
|
44,530,361
|
98.270 %
|
784,126
|
1.730 %
|
Trevor
Peters
|
42,520,594
|
93.834 %
|
2,793,893
|
6.166 %
|
Dr. Fotis
Kalantzis
|
44,646,513
|
98.526 %
|
667,974
|
1.474 %
|
Donald
Archibald
|
45,075,739
|
99.473 %
|
238,748
|
0.527 %
|
Al Foreman
|
45,145,244
|
99.627 %
|
169,243
|
0.373 %
|
Barbara
Munroe
|
44,783,365
|
98.828 %
|
531,122
|
1.172 %
|
Raffi
Asadorian
|
45,070,749
|
99.462 %
|
243,738
|
0.538 %
|
Dr. Jim
Lalonde
|
45,150,769
|
99.639 %
|
163,718
|
0.361 %
|
Dr. Chris
Savile
|
44,675,773
|
98.590 %
|
638,714
|
1.410 %
|
In addition, shareholders approved the appointment of KPMG LLP as
the Company's auditor for the ensuing year (99.423% of the votes
cast being in favour). The shareholders also approved the grant of
unallocated options issuable under Willow's stock option plan
pursuant to the requirements of the Toronto Stock Exchange. For
complete voting results on all matters approved at the Meeting,
please see the Company's Report of Voting Results dated
May 12, 2023 available on SEDAR at
www.sedar.com.
As previously announced on March 28,
2023, Mr. Raffi Asadorian was
appointed as an independent director to the board of directors of
Willow (the "Board") to succeed Mr. Sadiq Lalani who had served on the Board since
April 2019 and had decided not to
stand for re-election due to other commitments.
"We are thankful for Sadiq's years of service to Willow and wish
him the best in his new endeavors," said Trevor Peters, Chairman of the Board of the
Company. "At the same time, we welcome Raffi and his significant
financial expertise to our Board to help guide Willow on its
continued pathway toward successfully diversifying our portfolio
and further positioning the company for improved financial results
and revenue growth in the years ahead."
About Willow Biosciences
Inc.
Willow develops and produces precision fermented functional
ingredients for the health and wellness, food and beverage and
personal care markets. Willow's FutureGrownTM
biotechnology platform allows large-scale production with
sustainability at its core. Willow's R&D team has a proven
track record of developing and commercializing bio-based
manufacturing processes and products to benefit our B2B partners
and their customers.
SOURCE Willow Biosciences Inc.